DD212981A5 - Verfahren zur gewinnung von pankreatin - Google Patents
Verfahren zur gewinnung von pankreatin Download PDFInfo
- Publication number
- DD212981A5 DD212981A5 DD83258863A DD25886383A DD212981A5 DD 212981 A5 DD212981 A5 DD 212981A5 DD 83258863 A DD83258863 A DD 83258863A DD 25886383 A DD25886383 A DD 25886383A DD 212981 A5 DD212981 A5 DD 212981A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- isopropyl alcohol
- pancreatin
- autolysis
- concentration
- item
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 149
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 47
- 229940055695 pancreatin Drugs 0.000 claims abstract description 47
- 208000035404 Autolysis Diseases 0.000 claims abstract description 25
- 206010057248 Cell death Diseases 0.000 claims abstract description 25
- 230000028043 self proteolysis Effects 0.000 claims abstract description 25
- 239000000835 fiber Substances 0.000 claims abstract description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 239000000725 suspension Substances 0.000 claims abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 238000004062 sedimentation Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 238000005238 degreasing Methods 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 4
- -1 alkali metal bicarbonate Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 239000012137 tryptone Substances 0.000 claims description 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 102000004882 Lipase Human genes 0.000 description 12
- 108090001060 Lipase Proteins 0.000 description 12
- 239000004367 Lipase Substances 0.000 description 12
- 235000019421 lipase Nutrition 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- 239000004382 Amylase Substances 0.000 description 10
- 102000013142 Amylases Human genes 0.000 description 10
- 108010065511 Amylases Proteins 0.000 description 10
- 235000019418 amylase Nutrition 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 108010013369 Enteropeptidase Proteins 0.000 description 6
- 102100029727 Enteropeptidase Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/94—Pancreatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19823248587 DE3248587A1 (de) | 1982-12-30 | 1982-12-30 | Verfahren zur gewinnung von pankreatin |
DE19823248588 DE3248588A1 (de) | 1982-12-30 | 1982-12-30 | Verfahren zur gewinnung von pankreatin von hohem schuettgewicht |
Publications (1)
Publication Number | Publication Date |
---|---|
DD212981A5 true DD212981A5 (de) | 1984-08-29 |
Family
ID=25807022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD83258863A DD212981A5 (de) | 1982-12-30 | 1983-12-29 | Verfahren zur gewinnung von pankreatin |
Country Status (15)
Country | Link |
---|---|
US (1) | US4623624A (hu) |
EP (1) | EP0115023B1 (hu) |
AR (1) | AR232000A1 (hu) |
BR (1) | BR8307280A (hu) |
CA (1) | CA1208580A (hu) |
DD (1) | DD212981A5 (hu) |
DE (1) | DE3377506D1 (hu) |
DK (1) | DK173599B1 (hu) |
ES (1) | ES8407516A1 (hu) |
HU (1) | HU196435B (hu) |
MD (1) | MD411C2 (hu) |
PL (1) | PL141118B1 (hu) |
SU (1) | SU1644712A3 (hu) |
UA (1) | UA5996A1 (hu) |
YU (1) | YU45584B (hu) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100229754B1 (ko) * | 1989-11-24 | 1999-11-15 | 샬러 한스, 하우스 한스 루돌프 | 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
US5861291A (en) * | 1997-02-24 | 1999-01-19 | Biozymes Inc. | Method for producing pancreatin which contains low amounts of residual organic solvent and product thereof |
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
KR100367659B1 (ko) * | 2000-05-08 | 2003-01-14 | 주식회사 바이넥스 | 선택적 안정화제의 첨가에 따른 자가분해(autolysis)를 통한 고역가 판크레아틴의 제조방법 |
US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
CA2419572A1 (en) * | 2003-02-18 | 2004-08-18 | Axcan Pharma Inc. | High dosage protease formulation |
AU2004260961B2 (en) * | 2003-07-29 | 2010-05-20 | Abbott Laboratories Gmbh | Analytical method for pancreatin and comparable compositions |
PT1729797E (pt) * | 2004-03-22 | 2008-12-17 | Solvay Pharm Gmbh | Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos |
US7153504B2 (en) | 2004-07-30 | 2006-12-26 | Can Technologies, Inc. | Stabilized pancreas product |
WO2006121803A1 (en) | 2005-05-05 | 2006-11-16 | Sensient Flavors Inc. | Production of beta-glucans and mannans |
EP1913138B1 (en) | 2005-07-29 | 2016-08-24 | Abbott Laboratories GmbH | Processes for the manufacture of pancreatin powder with low virus content |
US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
TW200745337A (en) * | 2006-02-24 | 2007-12-16 | Aminotech As | Modified process |
US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
SG186648A1 (en) | 2007-02-20 | 2013-01-30 | Aptalis Pharma Ltd | Stable digestive enzyme compositions |
US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
WO2010002972A1 (en) * | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
EP2165717A1 (de) * | 2008-08-27 | 2010-03-24 | Nordmark Arzneimittel GmbH & Co.KG | Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
KR20170005192A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법 |
KR101694931B1 (ko) | 2009-01-06 | 2017-01-10 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
UA111726C2 (uk) | 2010-10-01 | 2016-06-10 | Апталіс Фарма Лімітед | Препарат панкреліпази низької сили з кишковорозчинним покриттям |
CN106310242B (zh) | 2011-04-21 | 2020-02-28 | 柯尔马克有限责任公司 | 用于治疗神经精神障碍的化合物 |
EP2741766B1 (en) | 2011-08-08 | 2015-10-07 | Aptalis Pharma Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
KR20160055123A (ko) * | 2013-07-22 | 2016-05-17 | 앨러간 파마슈티컬스 인터내셔널 리미티드 | 고효능 판크레아틴 약학적 조성물 |
US10993996B2 (en) | 2013-08-09 | 2021-05-04 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
BR112016000658A2 (pt) * | 2013-11-05 | 2018-03-20 | Allergan Pharmaceuticals International Limited | pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática |
CA2947998A1 (en) | 2014-06-19 | 2015-12-23 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
CN107073084B (zh) | 2014-11-05 | 2022-03-25 | 雅培制药股份有限公司 | 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法 |
WO2017172619A1 (en) | 2016-03-28 | 2017-10-05 | Abb Vie Inc. | Enzyme compositions with reduced viral and microbial contamination |
US11278603B2 (en) | 2016-03-28 | 2022-03-22 | Abbvie Inc. | Enzyme compositions with reduced viral and microbial contamination |
EP3688153A1 (en) | 2017-09-27 | 2020-08-05 | Abbott Laboratories GmbH | Enzyme compositions with reduced viral and microbial contamination |
CN108316036A (zh) * | 2018-01-25 | 2018-07-24 | 陕西科技大学 | 一种豆渣制备微纤化纤维素的方法 |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2024105193A1 (en) * | 2022-11-17 | 2024-05-23 | Koptyug Andrey V | Novel compounds and methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB928654A (en) * | 1960-10-25 | 1963-06-12 | Philips Nv | Improvements in or relating to the production of pancreatin |
GB1328202A (en) | 1969-06-17 | 1973-08-30 | Union International Co Ltd | Manufacture of pancreatin |
DE2106706B2 (de) * | 1971-02-12 | 1973-05-10 | Wilson Pharmaceutical & Chemical Corp., Chicago, 111. (V.St.A.) | Verfahren zur herstellung von pankreatin als trockenes pulver mit hoher proteolytischer, amylolytischer und lipolytischer aktivitaet |
MX4738E (es) | 1976-05-07 | 1982-08-25 | Nattermann A & Cie | Procedimiento para fabricar preparados enzimaticos ricos en lipasa |
DE2620289C2 (de) * | 1976-05-07 | 1982-05-19 | A. Nattermann & Cie GmbH, 5000 Köln | Herstellung eines lipasereichen Enzympräparates |
-
1983
- 1983-12-20 DE DE8383112809T patent/DE3377506D1/de not_active Expired
- 1983-12-20 EP EP83112809A patent/EP0115023B1/de not_active Expired
- 1983-12-23 US US06/565,220 patent/US4623624A/en not_active Expired - Lifetime
- 1983-12-28 CA CA000444332A patent/CA1208580A/en not_active Expired
- 1983-12-28 AR AR295280A patent/AR232000A1/es active
- 1983-12-28 PL PL1983245381A patent/PL141118B1/pl unknown
- 1983-12-28 YU YU252483A patent/YU45584B/sh unknown
- 1983-12-29 DD DD83258863A patent/DD212981A5/de not_active IP Right Cessation
- 1983-12-29 SU SU833682185A patent/SU1644712A3/ru active
- 1983-12-29 BR BR8307280A patent/BR8307280A/pt not_active IP Right Cessation
- 1983-12-29 DK DK198306055A patent/DK173599B1/da not_active IP Right Cessation
- 1983-12-29 ES ES528537A patent/ES8407516A1/es not_active Expired
- 1983-12-29 UA UA3682185A patent/UA5996A1/uk unknown
- 1983-12-29 HU HU834516A patent/HU196435B/hu not_active IP Right Cessation
-
1994
- 1994-12-29 MD MD95-0074A patent/MD411C2/ro unknown
Also Published As
Publication number | Publication date |
---|---|
AR232000A1 (es) | 1985-04-30 |
UA5996A1 (uk) | 1994-12-29 |
MD411C2 (ro) | 1996-06-30 |
HU196435B (en) | 1988-11-28 |
YU45584B (sh) | 1992-07-20 |
DE3377506D1 (en) | 1988-09-01 |
ES528537A0 (es) | 1984-09-16 |
EP0115023B1 (de) | 1988-07-27 |
PL141118B1 (en) | 1987-06-30 |
CA1208580A (en) | 1986-07-29 |
PL245381A1 (en) | 1984-10-22 |
DK605583A (da) | 1984-07-01 |
DK605583D0 (da) | 1983-12-29 |
SU1644712A3 (ru) | 1991-04-23 |
EP0115023A3 (en) | 1986-04-09 |
BR8307280A (pt) | 1984-08-07 |
EP0115023A2 (de) | 1984-08-08 |
DK173599B1 (da) | 2001-04-23 |
YU252483A (en) | 1986-10-31 |
ES8407516A1 (es) | 1984-09-16 |
US4623624A (en) | 1986-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0115023B1 (de) | Verfahren zur Gewinnung von Pankreatin | |
DE2619667A1 (de) | Pharmazeutisches mittel | |
DE2521814A1 (de) | Verfahren zum hydrolysieren von proteinen | |
EP0509008B1 (de) | Biomasse zur produktion von virus/virusantigen | |
CH645408A5 (de) | Verfahren zur herstellung von pectin aus pflanzengeweben. | |
DE3248588A1 (de) | Verfahren zur gewinnung von pankreatin von hohem schuettgewicht | |
DE1492959C3 (de) | Verfahren zur Gewinnung von Abbauprodukten von Proteinen | |
DE2001902A1 (de) | Verfahren zur Anreicherung von Proteinen | |
DE202018102546U1 (de) | Zellkulturmedium, welches von der chinesischen Kräutermedizin abgeleitete wässrige Extrakte enthält | |
EP0310757B1 (de) | Verfahren zur Herstellung eines Propolis-Äthanolextraktes | |
DE2447050C2 (de) | Verfahren zur Gewinnung von Proteasenhemmstoff | |
DE3248587A1 (de) | Verfahren zur gewinnung von pankreatin | |
EP0069995B1 (de) | Verfahren zur Herstellung eines Bienenpollengemisches mit verbesserter Resorbierbarkeit sowie ein zur Hyposensibilisierung geeignetes Bienenpollengemisch | |
DD149532A5 (de) | Verfahren zur herstellung von organextrakten mit hohem heparingehalt | |
WO1995014394A1 (de) | Verfahren zur aufbereitung von proteinen aus einer proteinhaltigen substanz | |
DE69915290T2 (de) | Verfahren zur extraktion eines bestandteiles von pflanzenmaterial | |
WO2017169311A1 (ja) | ネポジン高含有ギシギシ抽出物の製造方法及びネポジン高含有ギシギシ抽出物 | |
DE845485C (de) | Verfahren zur Herstellung von Magenschleimhautpraeparaten durch Selbstandauung | |
DE973249C (de) | Verfahren zur Gewinnung von injizierbaren Loesungen aus Frischplacenta | |
DE1961064A1 (de) | Verfahren zur Herstellung fermentativ nicht spaltbarer Pflanzen-extraktkonzentrate | |
JP2002017274A (ja) | プロポリス抽出物の粉末及びその製造方法 | |
DE19907723C2 (de) | Verfahren zur Herstellung eines pflanzlichen Proteinkonzentrats aus einer Proteine enthaltenden Ausgangssubstanz | |
US2799618A (en) | Glycosidal material having activity on the heart and vascular vessels and its preparation from plant sources | |
US2758056A (en) | Extraction of proteolytic enzymes from insulin-free pancreas glands | |
DE875640C (de) | Verfahren zur Gewinnung von proteolytischen Pankreasenzymen von Saeugetieren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENJ | Ceased due to non-payment of renewal fee | ||
ENJ | Ceased due to non-payment of renewal fee |